Claim 50% Off TipRanks Premium and Invest with Confidence
- Unlock hedge-fund level data and powerful investing tools designed to help you make smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis so your portfolio is always positioned for maximum potential
CanSino Biologics, Inc. Class H ( (HK:6185) ) has provided an update.
CanSino Biologics Inc. announced a supplemental update regarding its 2025 H Share Option Scheme, clarifying that the grant of H Share Options is contingent upon the scheme’s approval by shareholders at an upcoming Extraordinary General Meeting (EGM). The company plans to distribute a circular with more details about the scheme and the EGM notice to shareholders soon, which could impact the company’s stock option framework and shareholder engagement.
The most recent analyst rating on (HK:6185) stock is a Buy with a HK$66.60 price target. To see the full list of analyst forecasts on CanSino Biologics, Inc. Class H stock, see the HK:6185 Stock Forecast page.
More about CanSino Biologics, Inc. Class H
CanSino Biologics Inc. is a biotechnology company based in China, primarily engaged in the research, development, and commercialization of vaccine products. The company focuses on providing innovative vaccines to address global health challenges.
Average Trading Volume: 2,321,577
Technical Sentiment Signal: Buy
Current Market Cap: HK$14.4B
For detailed information about 6185 stock, go to TipRanks’ Stock Analysis page.